Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
- Disease/Condition
- Renal Cell Carcinoma
- Drug/Device/Intervention
- Pembrolizumab injection
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- University of Alabama at Birmingham
- Location
- Birmingham, United States of America
- Phase
- Phase 2
- Start date
- Dec 01, 2023
- End date
- Jun 30, 2025
- Enrollment
- 100 participants
Disease Free Survival (DFS) by Investigator's assessment as defined by RECIST 1.1
The goal of this Clinical Study is to understand the outcomes by informing therapy choice for
 adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease.
 
 The main question[s] it aims to answer are:
 
 - what is the progression free survival of a cohort of high risk resected RCC patients
 when treated based on MRD
 
 - what is the overall survival of high risk resected RCC patients when treated based on
 MRD
 
 Participants will forgo adjuvant therapy with pembrolizumab if they have no detectable
 molecular residual disease. Participants will continue on with standard of care pembrolizumab
 if they do appear to have molecular residual disease.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06005818
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06005818 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.